R. Stewart

发表

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

Yiming Li, L. Young, E. Carter, 2017, Oncoimmunology.

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

R. Wilkinson, S. Hammond, M. Oberst, 2014, Journal of Immunotherapy for Cancer.

A variant human IgG1-Fc mediates improved ADCC.

Pauline M Rudd, Michael P. Levens, L. Jermutus, 2011, Protein engineering, design & selection : PEDS.

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

L. Young, C. Leow, R. Wilkinson, 2017, Clinical Cancer Research.

Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1

T. Illidge, R. Wilkinson, S. Dovedi, 2014 .

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Paul D. Smith, S. Grosskurth, R. Wilkinson, 2017, Journal of Immunotherapy for Cancer.

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

B. Monk, A. Tinker, A. Oza, 2021, The Lancet. Oncology.

Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial

B. Monk, A. Oza, J. Ledermann, 2020 .

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy

R. Minter, A. Sandercock, J. Bradley, 2016, Oncotarget.

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

J. Hood, R. Wilkinson, N. Luheshi, 2021, mAbs.

Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody

V. Bedian, R. Wilkinson, I. Foltz, 2015, Cancer Immunology Research.

B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable alpha and beta genes of the T-cell receptor.

T. Eberlein, P. Goedegebuure, L. Montgomery, 2000, Surgery.

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors

M. Galsky, K. Yonemori, C. Chappey, 2022, JAMA oncology.

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors

M. Galsky, A. Bardia, C. Chappey, 2022, JAMA oncology.

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Paul D. Smith, S. Grosskurth, R. Wilkinson, 2017, Journal for immunotherapy of cancer.

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

I. Stratford, T. Illidge, R. Wilkinson, 2014, Cancer research.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

R. Emerson, M. Vignali, H. Robins, 2017, Clinical Cancer Research.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Simon J. Dovedi, D. Greenawalt, Dennis Wang, 2016, Cancer Immunology Research.

Development of PARP and Immune-Checkpoint Inhibitor Combinations.

T. Yap, P. Pilié, R. Stewart, 2018, Cancer research.

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.

B. Monk, A. Oza, J. Ledermann, 2021, The Lancet. Oncology.

PD-L1 blockade for cancer treatment: MEDI4736.

R. Stewart, R. Ibrahim, A. Shalabi, 2015, Seminars in oncology.

CD154 Tone Sets the Signaling Pathways and Transcriptome Generated in Model CD40-Pluricompetent L3055 Burkitt’s Lymphoma Cells1

A. Challa, L. Young, A. Eliopoulos, 2007, The Journal of Immunology.

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

Mohammad Tabrizi, Gadi Gazit Bornstein, Larry L. Green, 2007, Investigational New Drugs.

Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts

M. Galsky, A. Bardia, C. Chappey, 2020 .

BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).

D. Bajorin, S. Park, J. Rosenberg, 2022, Journal of Clinical Oncology.

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

T. Schumacher, C. Blank, J. Gadiot, 2012, Oncoimmunology.

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

D. Bajorin, S. Park, J. Rosenberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

E. Winer, P. Morris, I. C. Tudor, 2017 .

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Yeon-Hee Park, S. Im, K. Jung, 2021 .

Abstract 285: MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment

R. Hollingsworth, K. Sachsenmeier, S. Hammond, 2015 .

IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells.

M. Sleeman, R. Stewart, G. Rosignoli, 2017, Blood advances.

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.

C. Chappey, D. Hyman, T. Yap, 2019, Journal of Clinical Oncology.

Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development

V. Bedian, Suping Wang, M. Mccourt, 2011 .

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

L. Siu, L. Licitra, R. Haddad, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

Eleanor J. Cheadle, Jamie Honeychurch, R. Emerson, 2017, Clinical Cancer Research.

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

I. Stratford, T. Illidge, R. Wilkinson, 2014, Cancer research.

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine

S. Hammond, S. Khleif, R. Abu Eid, 2014, Journal of Immunotherapy for Cancer.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

D. Greenawalt, Dennis Wang, R. Sainson, 2016, Cancer Immunology Research.